NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock
09. August 2019 09:26 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care...
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
09. August 2019 09:22 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care...
NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update
12. November 2014 07:03 ET
|
NovaBay Pharmaceuticals, Inc.
Q3 Commercial Highlights:
Initiation of the marketing campaign and commercialization effort for NovaBay's new product, i-Lid™ Cleanser, with medical sales representatives deployed in 10...
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
20. März 2014 09:00 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
19. März 2014 16:32 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides a Clinical/Business Update
07. März 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Near-Term Clinical Catalysts:
• Viral Conjunctivitis Trial Results to be Reported mid-2014
• Start of Second Phase 2 in UCBE...
NovaBay CEO Comments on President Obama's 'Superbug' Budget Initiative and Reports by the CDC on Antibiotic Resistance
06. März 2014 15:22 ET
|
NovaBay Pharmaceuticals, Inc.
A recent journal article by NovaBay researchers describes the growing threat of resistance - and how the nation can fight it
EMERYVILLE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- NovaBay®...
NovaBay Pharmaceuticals Grants Principle Business Enterprises Exclusive Marketing and Distribution Rights in the US for NeutroPhase(R), an Advanced Wound and Skin Cleanser
26. Februar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Recent In Vitro Study, Published in a Peer-Reviewed Journal, Demonstrated that NeutroPhase is Best Among Products Tested and Kills Bacteria Quickly
New Minimally-Invasive Adjunctive Therapy...
NovaBay's NeutroPhase(R) is Best in Class in Laboratory Study of 19 Top Commercial Wound Cleansers
17. Februar 2014 09:30 ET
|
NovaBay Pharmaceuticals, Inc.
The In Vitro Study, Published in the Peer-Reviewed Journal Advances in Skin & Wound Care, Showed that NeutroPhase Kills Bacteria Quickly
Among the Products Tested, NeutroPhase Offered the Best...
NovaBay Pharmaceuticals to Present at the Annual Dialysis Conference in Atlanta
07. Februar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Nephrologist Allan Kavalich, MD, to Discuss Improvements in Infections Associated With Peritoneal Dialysis Catheters With Use of NeutroPhase - Pure 0.01% Hypochlorous Acid Solution
EMERYVILLE,...